



Clinical Characteristics and Outcomes of COVID-19 in Pediatric Cancer Patients: A Retrospective Cohort Study

Sara Badiepour¹, Sharareh Kamfar^{1,*}, Samin Alavi ¹, Shahnaz Armin ², Reza Taherian ³

¹ Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding Author: Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: kamfarsharareh@gmail.com

Received: 13 August, 2024; Revised: 23 September, 2024; Accepted: 24 October, 2024

Abstract

Background: The impact of COVID-19 on pediatric cancer patients remains a critical area of investigation.

Objectives: This study aimed to compare the clinical characteristics and outcomes of COVID-19 in children with and without malignancies.

Methods: A retrospective cohort study was conducted at Mofid Children's Hospital in Tehran, Iran, from July 2020 to December 2022. The study included 210 children with confirmed SARS-CoV-2 infection: 105 with malignancies (case group) and 105 without malignancies (control group). Clinical presentations, laboratory parameters, imaging findings, and outcomes were analyzed.

Results: Children with malignancies exhibited lower rates of fever ($P = 0.044$), respiratory distress ($P = 0.035$), and nausea/vomiting ($P = 0.002$). Significant differences in laboratory findings were observed between the case and control groups, including WBC count ($P = 0.007$), hemoglobin levels ($P < 0.001$), platelet count ($P = 0.002$), and ESR ($P = 0.001$). Ground-glass opacity on chest imaging was significantly associated with malignancy ($P = 0.003$). Although not statistically significant, the malignancy group showed a trend toward higher mortality ($OR = 2.686, P = 0.105$). Thrombotic events were rare in both groups.

Conclusions: Pediatric cancer patients with COVID-19 exhibited more severe symptoms and distinct laboratory and imaging findings compared to non-cancer patients. While mortality rates were similar, the trend toward higher risk in the malignancy group highlights the need for specialized management strategies for this vulnerable population.

Keywords: COVID-19, Pediatrics, Malignancy, Clinical Manifestations, Laboratory Findings, Imaging Findings

1. Background

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health, with varying effects across different population groups (1). While children generally experience milder symptoms compared to adults, certain subgroups, such as those with underlying morbidities, may be at higher risk for severe outcomes (2). Among these potentially vulnerable groups are children with malignancies, whose compromised immune systems, due to both their underlying condition and cancer treatments, may alter their response to SARS-CoV-2 infection (3). Although the peak of the pandemic has passed, understanding the impact of COVID-19 on pediatric

cancer patients remains crucial. The potential long-term consequences of COVID-19 in this population are still under investigation. Additionally, new SARS-CoV-2 variants continue to emerge, potentially affecting vulnerable populations differently. Insights from this study may prove useful in developing strategies for managing future infectious disease outbreaks in pediatric oncology settings.

Recent studies have emphasized the need for a comprehensive understanding of how COVID-19 affects pediatric patients with malignancies compared to their counterparts without cancer. The clinical presentation of COVID-19 in children can range from asymptomatic to severe, with common symptoms including fever, cough, and gastrointestinal disturbances (4, 5). Laboratory

findings often reveal alterations in WBC counts, inflammatory markers, and coagulation parameters (6, 7). Diagnostic tools such as reverse transcription-polymerase chain reaction (RT-PCR) and imaging techniques, particularly chest CT scans, have shown characteristic patterns that aid in diagnosing and monitoring disease progression (8). There is limited data on COVID-19 infection in children with cancer, and the interplay between malignancy and COVID-19 in pediatric patients remains an area of active research (9). Some studies suggest that children with cancer may experience more severe COVID-19 outcomes (10), while others report clinical courses similar to those of children without malignancies (11). Interestingly, at the beginning of the pandemic, it was speculated that patients with compromised immune systems might experience a milder clinical course (12).

2. Objectives

This study aimed to review the clinical symptoms, laboratory findings, and imaging results of COVID-19 in hospitalized children with malignancies, compared to their peers without malignancies, at Mofid Children's Hospital. The significant differences identified between these two groups could inform clinical decision-making and resource allocation in pediatric oncology units during the ongoing pandemic.

3. Methods

3.1. Study Design and Participants

We conducted a retrospective cohort study at Mofid Children's Hospital, a tertiary pediatric care center in Tehran, Iran, from July 2020 to December 2022. The study adhered to the principles of the Declaration of Helsinki and received approval from the Ethical Committee of Shahid Beheshti University of Medical Sciences ([IR.SBMU.RICH.REC.1400.026](#)). The requirement for informed consent was waived due to the retrospective nature of the study.

Medical records of all pediatric patients admitted during this period who tested positive for SARS-CoV-2 by RT-PCR were reviewed. Inclusion criteria were: (1) Age ≤ 18 years, and (2) confirmed SARS-CoV-2 infection by RT-PCR. Exclusion criteria included outpatients who had positive PCR tests for SARS-CoV-2 infection.

Out of 1,313 eligible children, 105 had concurrent malignancies and were assigned to the case group. We then selected 105 age- and sex-matched children without

malignancies as the control group using propensity score matching.

Propensity score matching is a statistical technique used to reduce confounding in observational studies by balancing covariates between groups (e.g., cases and controls). In this method, a propensity score is estimated for each individual, representing the probability of being assigned to a particular group (case or control) based on observed covariates. These scores are typically calculated using logistic regression. Once the propensity scores are estimated, individuals in the case group are matched to those in the control group based on similar propensity scores. This process creates pairs (or sets) of individuals with comparable characteristics across the groups, ensuring that any differences in outcomes between the groups are less likely to be due to confounding variables. By matching on the propensity score, the goal is to mimic the conditions of a randomized experiment, making the comparison between groups more valid (13).

3.2. Data Collection

We developed a data extraction form to collect the following information: Demographic data (age and sex), laboratory parameters [alanine aminotransferase (ALT) (14), prothrombin time (PT) (15), partial thromboplastin time (PTT), white blood cell count (WBC), hemoglobin (Hb), platelet count (Plt), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), and lung imaging findings chest X-ray and/or computed tomography (CT) (16) results]. The data were extracted from the hospital's electronic medical records system.

3.3. Statistical Analysis

We performed statistical analyses using SPSS software (version 26, IBM Corp., Armonk, NY, USA). The normality of continuous variables was assessed using the Shapiro-Wilk test. Descriptive statistics were presented as means and standard deviations for normally distributed continuous variables, medians and interquartile ranges for non-normally distributed continuous variables, and frequencies and percentages for categorical variables.

For between-group comparisons of patients with and without malignancy, we used the independent t-test for normally distributed continuous variables and the Mann-Whitney U test for non-normally distributed continuous variables. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, as appropriate. Logistic regression analysis

was employed to evaluate the association between imaging findings and malignancy status, adjusting for potential confounders identified in univariate analysis. The relationship between log-transformed WBC and imaging findings was assessed using linear regression models.

We calculated odds ratios to compare mortality between the malignancy and non-malignancy groups. Pearson's chi-square test was also used to examine the relationship between imaging findings and age groups. All statistical tests were two-tailed, and a P-value < 0.05 was considered statistically significant.

Given the sample size constraints of our study (210 children, 105 in each group), our ability to conduct comprehensive confounder analyses was limited. To address potential confounding, we used propensity score matching to control for age and sex, which were identified as the most critical potential confounders given our study design. While this approach helped balance these key variables between the case and control groups, we acknowledge that other potential confounders could not be fully accounted for in our analyses.

4. Results

4.1. Demographic and Clinical Characteristics

Our study included 210 children with confirmed SARS-CoV-2 infection: 105 with malignancies (case group) and 105 without malignancies (control group). The median age was 5 years (range: 0.08 - 17, IQR: 3 - 10.5), with 54.3% males and 45.7% females. In the malignancy group, acute lymphoblastic leukemia (ALL) was the most prevalent malignancy (n = 36, 34.3%), followed by brain tumors (n = 15, 14.3%). Acute myeloid leukemia (AML) and neuroblastoma were each observed in 11 children (10.5%). Other malignancies included Wilms' tumor (n = 10, 9.5%), non-Hodgkin's lymphoma (n = 8, 7.6%), Hodgkin's lymphoma (n = 3, 2.9%), and chronic myeloid leukemia (CML) (n = 1, 0.95%). Additionally, a variety of rare tumors were identified (n = 6, 5.7%).

In this study, the clinical presentation differed significantly between the case and control groups (Table 1). Overall, 31.4% of all patients were asymptomatic.

The results showed a statistically significant association between malignancy and fever (P = 0.044), respiratory distress (P = 0.035), and nausea/vomiting (P = 0.002). Conversely, seizures were more frequent in patients with COVID-19 without malignancy (P < 0.001).

Nine patients (4.3%) required intubation, with a higher number in the case group, although this difference was not statistically significant (P > 0.05).

4.2. Laboratory and Imaging Findings

Laboratory parameters revealed significant differences between the case and control groups (Table 2). White blood cell count (P = 0.007), hemoglobin (P < 0.001), Plt count (P = 0.002), and ESR (P = 0.001) exhibited statistically significant variations between the malignant and non-malignant groups. Among these parameters, ESR demonstrated the most clinical relevance.

Among the 114 patients (54.29%) who underwent chest imaging, ground-glass opacity (GGO) was significantly associated with malignancy (P = 0.003, Table 3).

4.3. Complications and Mortality

Thrombotic events were very rare, with only two cases observed in the initial cohort of 1,313 children: One case of deep vein thrombosis (DVT) in a child with a brain tumor and one case of cerebral sinus venous thrombosis (CSVT) in a child without an underlying disease.

No statistically significant association was found between mortality and malignancy status (P = 0.105, Table 4).

5. Discussion

The COVID-19 pandemic posed significant challenges for pediatric oncology patients, raising concerns about the vulnerability and outcomes of children with malignancies infected with SARS-CoV-2. Our study provided detailed data on the clinical presentation, laboratory findings, and imaging characteristics of COVID-19 in children with and without malignancies.

In our study, 1,313 eligible children were identified, of whom 105 with concurrent malignancies were included as cases. These cases were matched by age and sex with 105 controls without malignancies. While the matched design enhances comparability between the groups, the limited number of cases may reduce the power to detect smaller associations or interactions, which should be taken into account when interpreting the findings.

The demographic characteristics of our study population, including the age distribution and gender ratio, were consistent with those reported in several

Table 1. Clinical Manifestations of COVID in Patients with and Without Malignancy^a

Clinical Manifestations	With Malignancy	Without Malignancy	P-Value
Asymptomatic	21 (31.9)	45 (68.1)	< 0.001
Fever	41 (42.3)	56 (57.7)	0.044
Cough	12 (42.9)	16 (57.1)	0.432
Respiratory distress	10 (32.3)	21 (67.7)	0.035
Headache	3 (42.9)	4 (57.1)	1.000
Seizure	2 (9.5)	19 (90.5)	< 0.001
Rash	1 (20.0)	4 (80.0)	0.369
Myalgia	0 (0.0)	1 (100.0)	1.000
Nausea/vomiting	7 (23.3)	23 (76.7)	0.002
Abdominal pain	2 (25.0)	6 (75.0)	0.280
Diarrhea	8 (47.1)	9 (52.9)	0.816
Arthritis	0 (0.0)	3 (100.0)	0.246

^a Values are expressed as No. (%).

Table 2. Laboratory Parameters of COVID in Patients with and Without Malignancy^a

Laboratory Parameters	With Malignancy	Without Malignancy	P-Value
WBC	7147 ± 8276.69	8382 ± 5593.78	0.007
Hb	10.2 ± 2.24	11.6 ± 1.96	< 0.001
Plt	212984 ± 173.83	266839 ± 134884	0.002
ESR	40 ± 28.3	28 ± 22.6	0.001
CRP	21.86 ± 20.3	17.6 ± 17.5	0.097
LDH	781 ± 524.4	707 ± 545	0.174
AST	51 ± 46.4	86 ± 309.99	0.856
ALT	43 ± 41.1	65 ± 252.9	0.033
PT	13 ± 6.6	14 ± 12.2	0.818
PTT	33 ± 14.46	32 ± 8.3	0.778

Abbreviations: ALT, alanine aminotransferase; Plt, platelet; PT, prothrombin time; PTT, partial thromboplastin time; WBC, white blood cell count; Hb, hemoglobin; ESR, erythrocyte sedimentation rate; CRP, C-reactive.

^a Values are expressed as mean ± SD.

Table 3. Imaging Findings of COVID in Patients with and Without Malignancy

COVID Patients	Diffuse Infiltration	GGO	Consolidation	Perihilar Haziness	Emphysema	No Imaging Performed
With malignancy	7	9	8	9	1	56
Without malignancy	10	22	5	7	0	40
P-value	0.302	0.003	0.521	0.785	1.000	0.108
Odds ratio (95% CI)	0.095 (0.009, 1.071)	0.050 (0.005, 0.559)	0.346 (0.030, 3.982)	0.227 (0.022, 2.367)	2.69 (0.11, 67.3)	1.662 (0.893, 3.094)

other studies on pediatric COVID-19 cases (17, 18). Among the malignancy group in our study, ALL was the most prevalent, followed by brain tumors and AML, which aligns with global data on pediatric cancer distributions during the pandemic (19, 20).

The present study revealed significant differences in clinical presentation between children with and without malignancies. The higher prevalence of fever, respiratory distress, and gastrointestinal symptoms in the malignancy group was noteworthy and aligns with previous studies suggesting that immunocompromised

Table 4. Mortality in COVID Patients with and Without Malignancy

COVID Patients	Mortality in COVID Patients		Odds Ratio (95% CI)	P-Value
	Yes	No		
With malignancy	10	94	2.686 (0.815, 8.857)	0.105
Without malignancy	4	101		

patients may experience more severe symptoms during COVID-19 infection (10). In a systematic review of multisystem inflammatory syndrome (MIS-C) involving 7,297 children, the most common symptoms were fever (98.7%), rash (55.2%), and conjunctivitis (52.8%) (21).

A systematic review of 45 studies involving pediatric cancer patients across five continents highlighted that ALL was the most commonly reported malignancy, followed by AML and other solid tumors such as Wilms' tumor and neuroblastoma. The review also found that while the majority of infections were mild or moderate in severity, a significant subset of patients required hospitalization, with a notable incidence of severe COVID-19 cases (20).

The laboratory findings in our study provided valuable insights into potential differences in immune response between the two groups. Significant variations in WBC count, hemoglobin, Plt count, and ESR between the malignant and control groups suggest that the underlying malignancy may influence the hematological response to SARS-CoV-2 infection. A study by Tolunay et al., which reviewed medical records of pediatric patients with blood malignancies hospitalized due to COVID-19 at Children's Hospital Los Angeles, found that while most patients exhibited mild to moderate symptoms, significant hematologic abnormalities, including changes in WBC and Plt counts, were prevalent. These findings reflect the complex interplay between cancer treatment and COVID-19 infection (22).

These results underscore the need for careful monitoring of these parameters in pediatric cancer patients with COVID-19.

Imaging findings in the present study provided significant insights contributing to the literature on COVID-19 in pediatric patients, particularly those with malignancies. Ground-glass opacity (GGO) was significantly more associated with malignancy, suggesting that children with malignancies may experience more severe lung involvement. A comprehensive systematic review by Shelmerdine et al.

identified GGO as a common finding in pediatric COVID-19 cases (23). The increased observation of GGO in children with malignancies in the present study aligns with their findings, suggesting that underlying health conditions can influence imaging results. Additionally, we found a relationship between diffuse infiltration on chest imaging and increased WBC count, which may be explained by the occurrence of systemic inflammatory responses in pediatric COVID-19 patients.

While our study found no statistically significant difference in mortality between the malignancy and non-malignancy groups, the slightly higher odds of death in children with malignancies warrant careful consideration. This finding contrasts with some early pandemic hypotheses suggesting that immunosuppressed patients might experience a milder clinical course (12). However, it aligns with more recent studies indicating potentially worse outcomes for children with cancer who contract COVID-19 (15).

Recent global studies have provided further insights into COVID-19 outcomes in pediatric cancer patients. A global registry study by Mukkada et al. reported that while most pediatric cancer patients with COVID-19 experienced mild symptoms, a significant minority required hospitalization or intensive care support (24). Conversely, a study by Kebudi et al. found similar clinical presentations between pediatric cancer patients and the general pediatric population, contrasting with our observation of more severe symptoms in the malignancy group (25). These differences underscore the need for region-specific data to guide local clinical practices.

The very low incidence of thrombotic events in our cohort was encouraging, given the established concerns about COVID-19-associated coagulopathy.

While our study focused on immediate outcomes, the potential long-term effects of COVID-19 in pediatric cancer survivors warrant further investigation. Emerging evidence indicates that some COVID-19 survivors, including children, may experience persistent symptoms, commonly referred to as "long COVID." For

pediatric cancer patients, who already contend with long-term health challenges, the additional burden of this condition could have significant implications.

The findings of this study hold important implications for future pandemic preparedness in pediatric oncology settings. For instance, the higher prevalence of respiratory distress and ground-glass opacities in children with malignancies suggests that these patients may benefit from earlier and more aggressive respiratory support. As healthcare systems worldwide continue to refine their pandemic response plans, incorporating these insights can help optimize care for this vulnerable population during future outbreaks.

5.1. Limitations

Our study had several limitations that should be acknowledged. Its retrospective, single-center design may introduce potential biases and limit the generalizability of the findings. The relatively small sample size (210 children) constrained our ability to perform comprehensive confounder analyses and may have limited the generalizability of the results, particularly in subgroup analyses. While we controlled for age and sex through propensity score matching, other potential confounders, such as specific cancer types, treatment status, and comorbidities, could not be fully accounted for in our analyses. This limitation may have impacted our ability to detect more subtle differences between groups or to fully assess the independent effect of malignancy on COVID-19 outcomes.

The study period, spanning from July 2020 to December 2022, encompassed a time during which COVID-19 management strategies evolved, potentially influencing patient outcomes. We were also unable to account for the effects of specific cancer treatments or disease stages on COVID-19 outcomes. Furthermore, as our study predates the widespread availability of COVID-19 vaccines, we could not assess the impact of vaccination in this population.

5.2. Conclusions

In conclusion, our findings suggest that children with malignancies who contract COVID-19 may present with more severe symptoms and distinct laboratory and imaging findings compared to their counterparts without malignancies. Although mortality rates were not significantly different, the higher odds of death in

the malignancy group highlight the need for heightened vigilance and potentially more aggressive management strategies for this vulnerable population.

Future research should prioritize multi-center prospective studies with larger sample sizes to further elucidate the long-term outcomes and potential complications of COVID-19 in pediatric cancer patients and to more robustly assess the impact of potential confounders on these outcomes.

Footnotes

Authors' Contribution: Study concept and design: S. A.; Acquisition of data: S. B.; Analysis and interpretation of data: R. T.; Drafting of the manuscript: Sh. K.; Critical revision of the manuscript for important intellectual content: S. A.; Administrative, technical, and material support: Sh. A.; Study supervision: Sh. K.

Conflict of Interests Statement: The authors declared no conflict of interests.

Data Availability: Medical records retrieved from the hospital's Health Information System (HIS). The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: IR.SBMU.RICH.REC.1400.026 .

Funding/Support: There was no funding support.

Informed Consent: This was a retrospective cohort study extracted from the medical records.

References

1. Alwan NA, Burgess RA, Ashworth S, Beale R, Bhadelia N, Bogaert D, et al. Scientific consensus on the COVID-19 pandemic: we need to act now. *Lancet*. 2020;**396**(10260):e71-2. [PubMed ID: 33069277]. [PubMed Central ID: PMC7557300]. [https://doi.org/10.1016/S0140-6736\(20\)32153-X](https://doi.org/10.1016/S0140-6736(20)32153-X).
2. Tsaouri S, Makis A, Kosmeri C, Siomou E. Risk Factors for Severity in Children with Coronavirus Disease 2019: A Comprehensive Literature Review. *Pediatr Clin North Am*. 2021;**68**(1):321-38. [PubMed ID: 33228941]. [PubMed Central ID: PMC7392074]. <https://doi.org/10.1016/j.pcl.2020.07.014>.
3. Farrar DS, Drouin O, Moore Hepburn C, Baerg K, Chan K, Cyr C, et al. Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020-May 2021. *Lancet Reg Health Am*. 2022;**15**:100337. [PubMed ID: 35936225]. [PubMed Central ID: PMC9342862]. <https://doi.org/10.1016/j.lana.2022.100337>.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

- pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;**395**(10223):507-13. [PubMed ID: 32007143]. [PubMed Central ID: PMC7135076]. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;**395**(10223):497-506. [PubMed ID: 31986264]. [PubMed Central ID: PMC7159299]. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
 6. Al-Saadi E, Abdunabi MA. Hematological changes associated with COVID-19 infection. *J Clin Lab Anal*. 2022;**36**(1). e24064. [PubMed ID: 34783405]. [PubMed Central ID: PMC8646489]. <https://doi.org/10.1002/jcla.24064>.
 7. Gajendra S. Spectrum of hematological changes in COVID-19. *Am J Blood Res*. 2022;**12**(1):43-53. [PubMed ID: 35291254]. [PubMed Central ID: PMC8918700].
 8. Poortahmasebi V, Zandi M, Soltani S, Jazayeri SM. Clinical Performance of RT-PCR and Chest CT Scan for Covid-19 Diagnosis; A Systematic Review. *Frontiers Emergency Med*. 2020;**4**(2s).
 9. Haeusler GM, Ammann RA, Carlesse F, Groll AH, Averbuch D, Castagnola E, et al. SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients. *Eur J Cancer*. 2021;**159**:78-86. [PubMed ID: 34736044]. [PubMed Central ID: PMC8501219]. <https://doi.org/10.1016/j.ejca.2021.09.027>.
 10. Majeed A, Wright T, Guo B, Arora RS, Lam CG, Martiniuk AL. The Global Impact of COVID-19 on Childhood Cancer Outcomes and Care Delivery - A Systematic Review. *Front Oncol*. 2022;**12**:869752. [PubMed ID: 35463381]. [PubMed Central ID: PMC9023072]. <https://doi.org/10.3389/fonc.2022.869752>.
 11. Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in Children With Cancer in New York City. *JAMA Oncol*. 2020;**6**(9):1459-60. [PubMed ID: 32401276]. [PubMed Central ID: PMC7221844]. <https://doi.org/10.1001/jamaoncol.2020.2028>.
 12. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. *Clin Infect Dis*. 2021;**72**(2):340-50. [PubMed ID: 33501974]. [PubMed Central ID: PMC7337668]. <https://doi.org/10.1093/cid/ciaa863>.
 13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;**70**(1):41-55. <https://doi.org/10.1093/biomet/70.1.41>.
 14. Koca R, Bektas S, Altinyazar HC, Sezer T. Benign cephalic histiocytosis: a case report. *Ann Dermatol*. 2011;**23**(4):508-11. [PubMed ID: 22148022]. [PubMed Central ID: PMC3229948]. <https://doi.org/10.5021/ad.2011.23.4.508>.
 15. Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet*. 2020;**395**(10241):1919-26. [PubMed ID: 32473682]. [PubMed Central ID: PMC7255715]. [https://doi.org/10.1016/S0140-6736\(20\)31173-9](https://doi.org/10.1016/S0140-6736(20)31173-9).
 16. Hamadeh R, Soyiri I, Sreeramareddy C, Srinivasan V, Sripada K, Stovner L, et al. Five insights from the Global Burden of Disease Study 2019. *Lancet*. 2020;**396**(10258):1135-59. [PubMed ID: 33069324]. [PubMed Central ID: PMC7116361]. [https://doi.org/10.1016/S0140-6736\(20\)31404-5](https://doi.org/10.1016/S0140-6736(20)31404-5).
 17. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020;**145**(6). [PubMed ID: 32179660]. <https://doi.org/10.1542/peds.2020-0702>.
 18. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspá M, Lancellata L, Calo Carducci F, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020;**4**(9):653-61. [PubMed ID: 32593339]. [PubMed Central ID: PMC7316447]. [https://doi.org/10.1016/S2352-4642\(20\)30177-2](https://doi.org/10.1016/S2352-4642(20)30177-2).
 19. Hazarika M, Reddy R, Rai A, Roy P, Iqbal A, Barbhuiyan S, et al. COVID 19 Prevalence And Survival Outcome In Pediatric Cancer Patients Undergoing Chemotherapy: A Study From Tertiary Cancer Center Of North-East India. *Authorea*. 2024;**Preprints**. <https://doi.org/10.22541/au.170664916.67704828/v1>.
 20. Schlage S, Lehrnbecher T, Berner R, Simon A, Toepfner N. SARS-CoV-2 in pediatric cancer: a systematic review. *Eur J Pediatr*. 2022;**181**(4):1413-27. [PubMed ID: 35006377]. [PubMed Central ID: PMC8744033]. <https://doi.org/10.1007/s00431-021-04338-y>.
 21. Kamfar S, Zeinali V, Alaei F, Farahbakhsh N, Tabatabaee S, Mosallanejad A. COVID-19 Related Multi-System Inflammatory Syndrome in Children (MIS-C): A Systematic Review. *Arch Pediatric Infectious Dis*. 2024;**12**(3). <https://doi.org/10.5812/apid-139928>.
 22. Tolunay O, Celik U, Arslan I, Tutun B, Ozkaya M. Evaluation of Clinical Findings and Treatment Results of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Center Experience. *Front Pediatr*. 2022;**10**:848379. [PubMed ID: 35359885]. [PubMed Central ID: PMC8960421]. <https://doi.org/10.3389/fped.2022.848379>.
 23. Shelmerdine SC, Lovrenski J, Caro-Dominguez P, Toso S; Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce. Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings. *Pediatr Radiol*. 2020;**50**(9):1217-30. [PubMed ID: 32556807]. [PubMed Central ID: PMC7300372]. <https://doi.org/10.1007/s00247-020-04726-w>.
 24. Mukkada S, Bhakta N, Chantada GL, Chen Y, Vedaraju Y, Faughnan L, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. *Lancet Oncol*. 2021;**22**(10):1416-26. [PubMed ID: 34454651]. [PubMed Central ID: PMC8389979]. [https://doi.org/10.1016/S1470-2045\(21\)00454-X](https://doi.org/10.1016/S1470-2045(21)00454-X).
 25. Kebudi R, Kurucu N, Tugcu D, Hacisalihoglu S, Fisgin T, Ocak S, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study. *Pediatr Blood Cancer*. 2021;**68**(6). e28915. [PubMed ID: 33538100]. [PubMed Central ID: PMC7995085]. <https://doi.org/10.1002/pbc.28915>.